9-epi-Leucomycin A5 has been obtained from leucomycin A, (1) by the following reaction sequence.
Leucomycin A5 (I) was treated with Collins reagent (CrO3-pyridine) in the presence of water (13 %) to provide 9-dehydroleucomycin A, (II) in 95 % yield. The formyl group was internally protected by the reaction of II with acetic anhydride-K2C03 to afford 18,2'-di-O-acetyl-9-dehydroleucomycin A5-3,18-hemiacetal (III). Sodium borohydride reaction of II provided a 1: 1 mixture of natural I and its 9-epimer, 9-epi-leucomycin A, (IV), which were separated by silica gel chromatography.
It was observed that the antimicrobial activities of both enantiomers were virtually identical with some test strains but that of IV is reduced in comparison with I in some bacteria such as Staphylococcus epidermidis sp-al-1 and Streptococcus pyogenes N. Y. 5.
Studies on the alteration of antimicrobial activity arising from the configurational change of a substituent in the lactone ring of a macrolide have been quite limited.`)
This work describes the synthesis of 9-epi-leucomycin A, (IV) from leucomycin A, (I)°' and some comparison of the physicochemical properties and antimicrobial activities of these macrolides. In an initial attempt, the C-9 hydroxyl group of leucomycin was oxidized into the corresponding ketone with manganese dioxide') or the Cr03-pyridine complex') with only limited success; these methods provided the desired ketone in low yields. However, treatment of I with the CrO3-pyridine complex in the pre- The antimicrobial activities of leucomycin A5 (I), 9-dehydroleucomycin A5 (11) and 9-epl-leucomycin A, (IV) are compared in Table 1 . Although there was virtually no difference in antimicrobial activity between I and II, a comparison between I and IV maybe worth noting. The antimicrobial activities of l and IV sere nearly identical against Staplrvlococcus aureus, but I was about two times more active than IV against Staphylococcus epidermidis, Streptococcus po ogenes and Streptococcus faecalis.
Experimental Synthesis of 9-Dehydroleucomycin A,,
A solution of chromium trioxide (10 g) in water (10 ml) was added dropwise over 10 minutes to pyridine (40 ml) cooled in an ice bath.
To the mixture was added a solution OfICUCOrnycin A. (1) (10g) in pyridine (20 nil) and the reaction mixture was stirred for 2 hours at room temperature. It was then poured into cold water (600 ml) and the pH adjusted to 9 by adding aqueous ammonia. The mixture was extracted with chloroform (200 ml) and the organic layer was washed sequentially with dilute HC1 (p H 2, 200 ml), water (200 ml), and finally dilute aqueous ammonia (pH 9, 200 ml), dried over anhydrous magnesium sulfate, and concentrated in vacuo to provide 9.5 g powder of crude 9-dehydroleucomycin A., Synthesis of 18,2'-Di-O-acetyl-9-dehydroleucomycin A,-3,18-hemiacetal A mixture of 9-dehydroleucomycin A5 (II) (6 g) and anhydrous potassium carbonate (2.1 g) in acetic anhydride (12 ml) was stirred at 60°C for 16 hours. The reaction mixture was poured into water (200 ml) and the pH adjusted to 9 with aqueous ammonia. It was then extracted with chloroform (150 ml). The organic layer was washed with water (150 ml), dried over anhydrous magnesium sulfate and concentrated in vacuo to obtain 5.5 g of a powder which was purified by silica gel column (silica gel 60, Merck Art. 7734, 2.4 x 100 cm, each fraction 18 ml) eluting with benzene -acetone, 9: 1 -8 : 1 (v/v). The fractions, which showed a spot at Rf 0.39 on TLC (silica gel, Merck, Art. 5721, benzene -acetone, 4: 1, visualized with H2SO,), were collected and concentrated to provide 18,2'-di-O-acetyl-9-dehydroleucomycin A5-3, 18-hemiacetal (III) (3.2 g). III was further purified by column chromatography on silica gel using the same solvent system as described above. 
Synthesis of 9-epi-Leucomycin A5 (IV)
A solution of 18,2'-O-acetyl-9-dehydroleucomycin A5-3,18-hemiacetal (III) (1.45 g) in ethanol (26 ml) was treated with sodium borohydride (257 mg) at room temperature for 25 minutes. The reaction mixture was poured into 50 nil water and extracted with chloroform (50 ml). The extract was dried over magnesium sulfate and concentration in vacuo to afford 1.42 g residue, which was dissolved in methanol (15 ml) and treated with methanolic sodium methoxide (2.8 %, 0.6 ml) for 30 minutes at room temperature. The reaction mixture was poured into water (50 ml) and immediately extracted with chloroform (50 ml). The chloroform layer was dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude product was dissolved in methanol (15 ml) and the solution was refluxed overnight. The cooled reaction mixture was then concentrated and dried in vacuo to provide a 1: 1 mixture of leucomycin A, (I) and 9-epi-leucomycin A5 (IV) (1.2 g). Purification of I and IV required the following two steps; (1) the mixture was first purified by silica gel column chromatography (1 x 100 cm, each fraction 10 ml, eluting with benzene -acetone -methanol, 36: 4: 1 -32: 4: 1, v/v) to provide three fractions (first fractions; 215 mg, Rf 0.44: second fractions; 404 mg, two spots on TLC, Rf 0.44 and Rf 0.33: third fractions; 523 mg, Rf 0.33: TLC performed on silica gel, Merck Art. 5721 using chloroform -methanol -acetic acid -water, 80: 7: 7: 1, v/v) and (2) the first fractions (Rf 0.44, 215 mg) collected were further purified by alumina column chromatography (aluminum oxide 90 Art. 1097, Merck, 1 x 20 cm, each fraction 3 ml) to provide pure 9-epi-leucomycin A5 (IV) (148 mg) and impure 9-epi-leucomycin A5 (IV) (55 mg). Finally the third fractions (Rf 0.33, 523 mg) were again purified by alumina column chromatography (1 x 20 cm, 3 ml fraction, eluting with ethyl acetate -methanol, 50: 1, v/v) to give pure leucomycin A5 (I) (363 mg) and impure leucomycin A5 (I) (28 mg). 
